Neuronetics stock gains as Q3 revenue rises 12.5%

Neuronetics reported third-quarter revenue growth and narrower losses for the period ended September 30, according to Yahoo Finance. Revenue rose 12.5% year over year to 42.0 million US dollars, while adjusted EBITDA improved to 1.9 million US dollars from a loss of 4.7 million US dollars a year earlier.

Greenbrook Drives Quarterly Growth

Greenbrook revenue increased 20.1% to 26.2 million US dollars from 21.8 million US dollars in the prior-year quarter. NeuroStar revenue rose 1.8% to 15.8 million US dollars, as higher system sales offset weaker treatment-session revenue.

Gross margin expanded to 52.2% from 45.9%, supported by changes to the commercial strategy and improved revenue cycle management at Greenbrook clinics. Operating expenses fell 13% to 21.3 million US dollars, helping Neuronetics move to operating income of 0.5 million US dollars from an operating loss of 7.3 million US dollars.

The net loss attributable to shareholders narrowed to 1.7 million US dollars, or 0.02 US dollars per share, from 9.0 million US dollars, or 0.13 US dollars per share, in the year-earlier quarter. The company generated 0.8 million US dollars in combined operating and investing cash flow during the quarter, but ended September with total cash of 27.9 million US dollars, including restricted cash.

Revenue Outlook Remains Unchanged

Neuronetics maintained its 2026 revenue outlook of 160 million to 164 million US dollars. It raised the lower end of its gross-margin guidance to 49% from 48% and reduced its operating-expense forecast to 92.5 million to 95.5 million US dollars.

The company now expects combined operating and investing cash flow to be negative 10 million to negative 12 million US dollars for 2026. Investors will therefore weigh the improving quarterly profitability against continued cash use and the need for Greenbrook growth to persist.

Stock Quote And Investor Context

Neuronetics stock traded at 1.96 euros on Lang & Schwarz at 14:02 CET on Tuesday, November 10, 2026. The quote is presented without a daily Xetra comparison.

The S&P 500 provides the broader US market backdrop for investors tracking US-listed medical technology shares.

Neuronetics is also pursuing an accelerated TMS treatment protocol under FDA review and has agreed to a Wave Neuroscience distribution arrangement for post-traumatic stress disorder applications, subject to regulatory clearance. More news and analyses on Neuronetics stock.